<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534403</url>
  </required_header>
  <id_info>
    <org_study_id>SL0027</org_study_id>
    <nct_id>NCT01534403</nct_id>
  </id_info>
  <brief_title>Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects</brief_title>
  <official_title>A Phase 2, Multicenter, Open-label, Long-term, Extension Study to Assess the Safety of Epratuzumab Treatment in Japanese Subjects With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an open-labeled extension study to continue to assess the safety and
      tolerability of Epratuzumab in moderate to severe SLE subjects who have previously
      participated in SL0026 [NCT01449071] phase I/II trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects reporting at least 1 Adverse Event (AE) during the Treatment Period (maximum 100 weeks)</measure>
    <time_frame>up to Week 100</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in levels of total B Cells in the peripheral blood circulation at Week 96</measure>
    <time_frame>From Baseline (Week 0) to Week 96</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in levels of Monocyte in the peripheral blood circulation at Week 96</measure>
    <time_frame>From Baseline (Week 0) to Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in levels of NK-Cells (Natural Killer-Cells) in the peripheral blood circulation at Week 96</measure>
    <time_frame>From Baseline (Week 0) to Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in levels of total T Cells in the peripheral blood circulation at Week 96</measure>
    <time_frame>From Baseline (Week 0) to Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epratuzumab plasma concentration at Week 96</measure>
    <time_frame>Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects reporting anti-Epratuzumab in plasma at Week 96</measure>
    <time_frame>Week 96</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Epratuzumab 4x600 mg every 12 weeks Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Epratuzumab</intervention_name>
    <description>Epratuzumab 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, 39, 48, 49, 50, 51, 60, 61, 62, 63, 72, 73, 74, 75, 84, 85, 86, and 87)</description>
    <arm_group_label>Epratuzumab 4x600 mg every 12 weeks Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has completed the double-blind study SL0026 [NCT01449071] or terminated
             prematurely at Week 8 or later in SL0026 [NCT01449071] due to lack of efficacy

          -  Women of childbearing potential must agree to use an acceptable method of birth
             control/Written Informed Consent

        Exclusion Criteria:

          -  Subjects with active, severe SLE disease activity which involves the renal system and
             active, severe, neuropsychiatric SLE, defined as any neuropsychiatric element scoring
             British Isles Lupus Assessment Group Index (BILAG) level A

          -  Subjects with concurrent relevant medical conditions like defined chronic infections
             or high risk of new significant infections

          -  Substance abuse or dependence

          -  Significant hematologic abnormalities

          -  History of malignant cancer

          -  Subjects with any other condition which, in the investigator's judgment, would make
             the subject unsuitable for inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>10</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>11</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3</name>
      <address>
        <city>Kitakyusyu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>8</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2012</study_first_submitted>
  <study_first_submitted_qc>February 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2012</study_first_posted>
  <disposition_first_submitted>April 11, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 11, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 6, 2016</disposition_first_posted>
  <last_update_submitted>April 11, 2016</last_update_submitted>
  <last_update_submitted_qc>April 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>B-cell immunotherapy</keyword>
  <keyword>Epratuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

